

Balazs Halmos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1220301/publications.pdf>

Version: 2024-02-01

71
papers

5,110
citations

236612

25
h-index

118652

62
g-index

74
all docs

74
docs citations

74
times ranked

9806
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
2	Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. <i>Cancer Discovery</i> , 2020, 10, 935-941.	7.7	643
3	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1657-1669.	0.5	395
4	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1493-1502.	0.5	288
5	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene Mutations. <i>Journal of Clinical Oncology</i> , 2016, 34, 794-802.	0.8	287
6	Seroconversion rates following COVID-19 vaccination among patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1081-1090.e2.	7.7	285
7	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1393-1399.	0.5	169
8	AXL kinase as a novel target for cancer therapy. <i>Oncotarget</i> , 2014, 5, 9546-9563.	0.8	164
9	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2017, 12, 932-942.	0.5	129
10	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
11	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	12.5	103
12	Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	1.1	90
13	Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. <i>Nature Cancer</i> , 2021, 2, 392-399.	5.7	85
14	<i>RICTOR</i> Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 1262-1270.	7.7	84
15	Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 105-105.	0.8	83
16	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	1.1	71
17	Continuous Activity Monitoring During Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1061-1065.	0.4	52
18	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1031-1035.	0.5	44

#	ARTICLE	IF	CITATIONS
19	Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 105, 745-751.	0.4	44
20	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?. Neuro-Oncology, 2015, 17, 1022-1028.	0.6	39
21	Effects of β -Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 575.	1.0	39
22	Update in Lung Cancer 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 283-294.	2.5	36
23	Sunitinib activates Axl signaling in renal cell cancer. International Journal of Cancer, 2016, 138, 3002-3010.	2.3	32
24	Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. CytoJournal, 2014, 11, 12.	0.8	32
25	Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Cancer Cell, 2022, 40, 343-345.	7.7	32
26	Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1. PLoS ONE, 2014, 9, e106349.	1.1	27
27	DNA Polymerase β Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity. Oncologist, 2017, 22, 497-502.	1.9	24
28	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	0.8	24
29	EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets and Therapy, 2017, Volume 8, 147-159.	1.3	23
30	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	1.9	23
31	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Oncologist, 2015, 20, 1298-1303.	1.9	19
32	¹⁸ F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 372-380.	0.4	19
33	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Management, 2020, 9, LMT36.	1.5	19
34	Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Translational Lung Cancer Research, 2021, 10, 2148-2162.	1.3	19
35	Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).. Journal of Clinical Oncology, 2016, 34, 111-111.	0.8	15
36	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. Annals of Translational Medicine, 2017, 5, 377-377.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Positron Emission Tomographyâ€“Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 709-715.	0.4	14
38	A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS $\geq 1\%$ Metastatic NSCLC. <i>Cancers</i> , 2020, 12, 3648.	1.7	14
39	INI-1 (SMARCB1)â€“Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies. <i>Oncologist</i> , 2020, 25, 738-744.	1.9	14
40	Update in Lung Cancer 2015. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 661-671.	2.5	13
41	Circulating Tumor DNA in Nonâ€“Small-Cell Lung Cancer: A Primer for the Clinician. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	11
42	Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+â€“bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison. <i>Lung Cancer</i> , 2021, 155, 175-182.	0.9	11
43	Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination. <i>Cancer Research</i> , 2022, 82, 1365-1379.	0.4	11
44	Update in Lung Cancer and Oncological Disorders 2010. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 297-302.	2.5	6
45	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 137-147.	1.0	6
46	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8073-8073.	0.8	6
47	Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysis. <i>Future Oncology</i> , 2020, 16, 1585-1595.	1.1	5
48	Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC â€œcapitulateâ€?. <i>Translational Lung Cancer Research</i> , 2018, 7, S321-S325.	1.3	4
49	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2020, 136, 56-58.	0.6	3
50	Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8020-8020.	0.8	3
51	A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virusâ€“associated head and neck squamous cell cancer.. <i>Journal of Clinical Oncology</i> . 2018. 36. TPS6093-TPS6093.	0.8	3
52	Indirect comparison of pembrolizumab monotherapy versus nivolumab+Ipilimumab in first-line metastatic lung cancer. <i>Immunotherapy</i> , 2022, 14, 295-307.	1.0	3
53	Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2022, 17, 187-192.	1.7	3
54	Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3

#	ARTICLE	IF	CITATIONS
55	Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. <i>Oncologist</i> , 2021, 26, 224-230.	1.9	2
56	Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community. <i>Acta Oncologica</i> , 2021, 60, 559-563.	0.8	2
57	Improving lung cancer screening in the HIV population.. <i>Journal of Clinical Oncology</i> , 2019, 37, 69-69.	0.8	2
58	Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).. <i>Journal of Clinical Oncology</i> , 2016, 34, e15525-e15525.	0.8	2
59	Molecular Testing in Lung Cancer: Where to Draw the Line?. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 787-789.	1.2	1
60	Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100128.	0.6	1
61	Emerging uses of biomarkers in lung cancer management. <i>Annals of Translational Medicine</i> , 2017, 5, 370-370.	0.7	1
62	The impact of primary care access on mortality in lung cancer patients from Bronx, New York.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18614-e18614.	0.8	1
63	Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive genomic profiling.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8073-8073.	0.8	0
64	Rictor amplification to define a novel and unique subset of lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8027-8027.	0.8	0
65	Institutional cohort study of HIV-positive patients with lung cancer: Implications for screening?. <i>Journal of Clinical Oncology</i> , 2018, 36, e13582-e13582.	0.8	0
66	Impact and diagnostic gaps of multiplex genomic profiling (MGP) in an academic community-based cancer center.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24154-e24154.	0.8	0
67	Early determination of benefit or futility in treating NSCLC using the LCSS 3-Item Global Index (3-IGI).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9086-9086.	0.8	0
68	Survival disparities among African American (AA) patients (pts) with EGFR-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9054-9054.	0.8	0
69	Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 643-643.	0.8	0
70	Molecular analysis of advanced colorectal cancer in an ethnically diverse patient population at a single institution.. <i>Journal of Clinical Oncology</i> , 2019, 37, 702-702.	0.8	0
71	How SOLID is the immune system's response to the deadly duo of lung cancer and SARS-CoV-2?. <i>Translational Lung Cancer Research</i> , 2022, 11, 126-131.	1.3	0